Unlocking GLP-1: Genetic Clues to Drug Response Emerge

Researchers reported that specific genetic variants can help predict how individuals respond to GLP1 receptor agonist medicines used for weight loss, including semaglutide and tirzepatide, as well as the likelihood of certain side effects. The findings were published in Nature and were based on a genome-wide association study of 27,885 people receiving GLP1 receptor agonist therapy.

The study identified a missense variant in the GLP1R gene that was significantly associated with stronger medication effectiveness. According to the researchers, each copy of the effect allele predicted an additional 0.76 kg of weight loss, linking a drug-target gene variant to measurable differences in outcomes among treated individuals.

Beyond efficacy, the analysis also connected genetic variation to tolerability. Variants in both GLP1R and GIPR were associated with the incidence of nausea or vomiting . The researchers reported that the GIPR association was observed specifically among individuals using tirzepatide , indicating that side-effect risk may differ by medication and genetic background.

Taken together, the results support the idea that differences in genes encoding drug targets contribute directly to the wide person-to-person variation seen in response to GLP1 receptor agonist therapy. The researchers said these genetic signals could enable patient stratification based on expected benefit and side-effect risk, which could be relevant for clinical decision-making where multiple treatment options exist.

In practical terms, the study’s authors said the findings lay groundwork for precision-medicine approaches in obesity management. They described potential uses that include guiding drug selection, informing dosage choices, and shaping dose-escalation strategies for patients, with the aim of aligning treatment plans more closely to an individual’s predicted response profile.

At the same time, the report leaves open questions about how quickly such genetic insights can be translated into routine care and how they would be implemented across different health systems. The study establishes genetic associations in a large treated population, but the pathway from association findings to standardized clinical tools and workflows was not detailed in the published summary.